PubRank

L M Lichtenstein

Author PubWeight™ 466.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science 1968 4.38
2 Modulation of inflammation and immunity by cyclic AMP. Science 1974 4.31
3 The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol 1972 3.51
4 Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997 2.91
5 Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes. J Immunol 1972 2.70
6 A reappraisal of sting challenges: to whom should we offer venom immunotherapy? J Allergy Clin Immunol 1994 2.65
7 Anaphylaxis. N Engl J Med 1991 2.53
8 Histamine augments leukocyte adenosine 3',5'-monophosphate and blocks antigenic histamine release. Science 1971 2.47
9 Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol 2001 2.38
10 Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983 2.37
11 The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1990 2.35
12 A case for venom treatment in anaphylactic sensitivity to hymenoptera sting. N Engl J Med 1974 2.33
13 Inhibition of histamine release by histamine controlled by H2 receptor. Nature 1973 2.19
14 IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 1995 2.18
15 Immunological aspects of allergic asthma. Annu Rev Immunol 1994 2.17
16 Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. J Clin Invest 1973 2.16
17 Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996 2.13
18 A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978 2.08
19 Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000 2.05
20 Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest 1983 2.05
21 The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine. J Pharmacol Exp Ther 1975 2.02
22 Histamine release from human leukocytes: studies with deuterium oxide, colchicine, and cytochalasin B. J Clin Invest 1972 1.98
23 Molecular identification of an IgE-dependent histamine-releasing factor. Science 1995 1.95
24 Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest 1973 1.94
25 The immediate allergic response: in vitro separation of antigen activation, decay and histamine release. J Immunol 1971 1.93
26 Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985 1.84
27 Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med 1968 1.84
28 Epidemiology of insect venom sensitivity. JAMA 1989 1.83
29 Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest 1971 1.80
30 Human lung mast cells: purification and characterization. J Immunol 1982 1.78
31 The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol 1971 1.78
32 Generation of leukotrienes by purified human lung mast cells. J Clin Invest 1982 1.77
33 The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release. J Immunol 1971 1.73
34 The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol 1992 1.72
35 Release of slow reacting substance of anaphylaxis (SRS-A) from human leukocytes by the calcium ionophore A23187. J Immunol 1976 1.72
36 IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest 1978 1.71
37 Basophil "releasability" in patients with asthma. Am Rev Respir Dis 1980 1.70
38 The effects of a series of prostaglandins on in vitro models of the allergic response and cellular immunity. Prostaglandins 1972 1.67
39 Physiologic manifestations of human anaphylaxis. J Clin Invest 1980 1.65
40 Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol 1973 1.63
41 Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001 1.63
42 IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973 1.58
43 Routine use of penicillin skin testing on an inpatient service. N Engl J Med 1971 1.58
44 Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol 1997 1.55
45 Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000 1.54
46 Identification of basophil granulocytes as a site of allergic histamine release. J Immunol 1972 1.52
47 In vitro studies of human reaginic allergy. Adv Immunol 1968 1.50
48 Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol 1992 1.48
49 Arachidonic acid metabolism in purified human lung mast cells. J Immunol 1984 1.47
50 Antigen-specific IgE and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen-induced late phase reactions. Clin Exp Allergy 2001 1.46
51 Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. J Allergy Clin Immunol 1976 1.45
52 The mechanism of basophil histamine release induced by antigen and by the calcium ionophore A23187. J Immunol 1975 1.45
53 Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement. J Clin Invest 1985 1.45
54 Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol 1991 1.45
55 Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol 1994 1.44
56 Kinins are generated during experimental rhinovirus colds. J Infect Dis 1988 1.44
57 Properties of a subpopulation of T cells bearing histamine receptors. J Clin Invest 1975 1.43
58 Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis 1988 1.43
59 Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. N Engl J Med 1969 1.42
60 Studies on the mechanism of hypersensitivity phenomena. XI. The effect of normal human serum on the release of histamine from human leukocytes by ragweed pollen antigen. J Immunol 1966 1.41
61 Cutaneous late-phase response in food-allergic children and adolescents with atopic dermatitis. Clin Exp Allergy 1993 1.41
62 Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest 1983 1.41
63 Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis 1990 1.40
64 Platelet activation during antigen-induced airway reactions in asthmatic subjects. N Engl J Med 1981 1.40
65 Induction of histamine secretion by polycations. Biochim Biophys Acta 1980 1.39
66 Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis 1991 1.38
67 Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 1984 1.38
68 Heterogeneity of human mast cells. J Immunol 1983 1.37
69 Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1991 1.37
70 Insect allergy: the state of the art. J Allergy Clin Immunol 1979 1.35
71 Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. J Immunol 1995 1.33
72 Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. J Immunol 1983 1.33
73 Antigen-induced IgE-mediated degranulation of human basophils. Lab Invest 1980 1.32
74 Studies of IgE-dependent histamine releasing factors: heterogeneity of IgE. J Immunol 1987 1.32
75 Recombinant IL-3 induces histamine release from human basophils. J Immunol 1989 1.31
76 Studies on the mechanism of lymphocyte-mediated cytolysis. 3. The role of microfilaments and microtubules. J Immunol 1973 1.31
77 Allergy to insect stings. I. Diagnosis of IgE-mediated hymenoptera sensitivity by venom-induced histamine release. J Allergy Clin Immunol 1974 1.30
78 A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968 1.28
79 Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. J Immunol 1986 1.28
80 Eosinophil chemotactic factor (ECF). I. Release from polymorphonuclear leukocytes by the calcium ionophore A23187. J Immunol 1976 1.27
81 A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies. Ann Intern Med 1971 1.27
82 Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999 1.26
83 Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996 1.25
84 In vitro reversed anaphylaxis: characteristics of anti-IgE mediated histamine release. Immunology 1970 1.24
85 Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration. J Clin Invest 1989 1.23
86 IgE-dependent IL-4 secretion by human basophils. The relationship between cytokine production and histamine release in mixed leukocyte cultures. J Immunol 1994 1.23
87 Eosinophil chemotactic factor (ECF). II. Release from human polymorphonuclear leukocytes during phagocytosis. J Immunol 1976 1.22
88 Release of eosinophil chemotactic factor from human polymorphonuclear neutrophils by calcium ionophore A23187 and phagocytosis. Nature 1975 1.21
89 Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis 1988 1.21
90 Hyperosmolar triggering of histamine release from human basophils. J Clin Invest 1981 1.21
91 Contraction of guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine. Am J Physiol 1981 1.21
92 Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release. J Clin Invest 1979 1.20
93 Anaphylactic release of a basophil kallikrein-like activity. I. Purification and characterization. J Clin Invest 1979 1.20
94 Diagnostic tests in ragweed hay fever. A comparison of direct skin tests, IgE antibody measurements, and basophil histamine release. J Allergy Clin Immunol 1973 1.20
95 Human basophils: mediator release and cytokine production. Adv Immunol 2001 1.20
96 The purification of human basophils. J Immunol 1980 1.20
97 The role of agonists that activate adenylate cyclase in the control of cAMP metabolism and enzyme release by human polymorphonuclear leukocytes. J Immunol 1980 1.19
98 Regulation of human basophil mediator release by cytokines. I. Interaction with antiinflammatory steroids. J Immunol 1989 1.17
99 IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest 1976 1.17
100 Effects of arachidonic acid and its metabolites on antigen-induced histamine release from human basophils in vitro. J Immunol 1979 1.17
101 Basophil and mast cell degranulation: ultrastructural analysis of mechanisms of mediator release. Fed Proc 1983 1.15
102 Cyclic AMP metabolism in asthma: studies with leukocytes and lymphocytes. J Allergy Clin Immunol 1974 1.15
103 Heavy water enhances IgE-mediated histamine release from human leukocytes: evidence for microtubule involvement.. 1. Proc Soc Exp Biol Med 1972 1.15
104 Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments. Am Rev Respir Dis 1982 1.14
105 Inhibition of basophil histamine release by anti-inflammatory steroids. Nature 1981 1.14
106 Qualitative characteristics of histamine release from human basophils by covalently cross-linked IgE. J Immunol 1981 1.13
107 Selective display of histamine receptors on lymphocytes. Science 1977 1.13
108 Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980 1.12
109 Studies on the mechanisms of hypersensitivity phenomena. XII. An in vitro study of the reaction between ragweed pollen antigen, allergic human serum and ragweed-sensitive human leukocytes. J Immunol 1966 1.12
110 Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest 1985 1.11
111 Interactions of the complement system with endotoxic lipopolysaccharides in immunoglobulin-deficient sera. J Exp Med 1970 1.11
112 Comparative studies of human basophils and mast cells. Fed Proc 1983 1.11
113 Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. J Immunol 1987 1.11
114 Regulation of human basophil and lung mast cell function by cyclic adenosine monophosphate. J Immunol 1988 1.11
115 Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 1970 1.11
116 Adenosine receptor on human basophils: modulation of histamine release. J Immunol 1979 1.11
117 Ultrastructural immunogold localization of prostaglandin endoperoxide synthase (cyclooxygenase) to non-membrane-bound cytoplasmic lipid bodies in human lung mast cells, alveolar macrophages, type II pneumocytes, and neutrophils. J Histochem Cytochem 1992 1.10
118 Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol 1982 1.10
119 Increase in histamine receptors on thymus-derived effector lymphocytes during the primary immune response to alloantigens. Nature 1973 1.10
120 Characterization of a specific adenosine receptor on human lymphocytes. J Immunol 1978 1.10
121 Anaphylactic release of prostaglandins from human lung in vitro. Am Rev Respir Dis 1980 1.08
122 Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 2001 1.08
123 Identification of histamine releasing factor(s) in the late phase of cutaneous IgE-mediated reactions. J Immunol 1986 1.07
124 Eosinophil transendothelial migration induced by cytokines. II. Potentiation of eosinophil transendothelial migration by eosinophil-active cytokines. J Immunol 1994 1.07
125 Immunotherapy of hay fever with ragweed antigen E: comparisons with whole pollen extract and placebos. J Allergy 1968 1.07
126 Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. Proc Natl Acad Sci U S A 1988 1.07
127 Differences in the behavior of cytoplasmic granules and lipid bodies during human lung mast cell degranulation. J Cell Biol 1984 1.07
128 A comparison of the osmotic activation of basophils and human lung mast cells. Am Rev Respir Dis 1987 1.07
129 Interactions of the complement system with endotoxic lipopolysaccharide: the generation of an anaphylatoxin. Immunology 1969 1.06
130 Human lung macrophage-derived histamine-releasing activity is due to IgE-dependent factors. J Immunol 1986 1.05
131 Interaction between hyperosmolar and IgE-mediated histamine release from basophils and mast cells. Am Rev Respir Dis 1984 1.05
132 Effects of passive antibody in bee venom anaphylaxis. Johns Hopkins Med J 1978 1.05
133 The transition from specific to nonspecific desensitization in human basophils. J Immunol 1981 1.05
134 Epidemiologic study of insect allergy in children. II. Effect of accidental stings in allergic children. J Pediatr 1983 1.04
135 In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody. Blood 1998 1.04
136 Tryptase and histamine as markers to evaluate mast cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutions. J Allergy Clin Immunol 1992 1.03
137 Antigen-specific desensitization of human basophils. J Immunol 1979 1.03
138 Role of receptor aggregation in triggering IgE-mediated reactions. Fed Proc 1982 1.03
139 The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic steroid pretreatment. Am Rev Respir Dis 1988 1.02
140 Role of human basophils and mast cells in the pathogenesis of allergic diseases. J Allergy Clin Immunol 1985 1.02
141 Isolation and characterization of human intestinal mucosal mast cells. J Immunol 1985 1.02
142 Upregulation of FcepsilonRI on human basophils by IgE antibody is mediated by interaction of IgE with FcepsilonRI. J Allergy Clin Immunol 1999 1.02
143 In vivo suppression of the immune response to alloantigen by cholera enterotoxin. J Clin Invest 1973 1.01
144 Isolation and characterization of allergens from ragweed pollen. IV. Biochemistry 1967 1.01
145 Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Respir Dis 1986 1.01
146 Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. J Immunol 1991 1.01
147 Blood and bronchoalveolar eosinophils in allergic subjects after segmental antigen challenge: surface phenotype, density heterogeneity, and prostanoid production. J Allergy Clin Immunol 1994 1.01
148 Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects. J Allergy Clin Immunol 2001 1.00
149 Human lung macrophages induce histamine release from basophils and mast cells. Am Rev Respir Dis 1985 1.00
150 Influx of kininogens into nasal secretions after antigen challenge of allergic individuals. J Clin Invest 1985 0.99
151 Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988 0.99
152 Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 1987 0.98
153 Diagnosis of allergy to stinging insects by skin testing with Hymenoptera venoms. Ann Intern Med 1976 0.98
154 Inhibition of basophil histamine release by anti-inflammatory steroids. II. Studies on the mechanism of action. J Immunol 1982 0.98
155 Differential regulation of IL-4 and IL-13 secretion by human basophils: their relationship to histamine release in mixed leukocyte cultures. J Immunol 1998 0.98
156 Interleukin-1 is released at sites of human cutaneous allergic reactions. J Allergy Clin Immunol 1990 0.98
157 Release of leukocyte kallikrein mediated by IgE. Nature 1975 0.98
158 Immunophenotyping and functional analysis of purified human uterine mast cells. Blood 1992 0.97
159 Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses. J Allergy Clin Immunol 1997 0.97
160 Indomethacin enhances response of human bronchus to antigen. Am Rev Respir Dis 1985 0.97
161 Release of slow reacting substance of anaphylaxis from human leukocytes. J Immunol 1974 0.97
162 Lipoxygenase products modulate histamine release in human basophils. Nature 1981 0.97
163 Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen. J Allergy Clin Immunol 1990 0.97
164 Basophil histamine release induced by a substance from stimulated human platelets. J Immunol 1986 0.97
165 Terfenadine, an H1 antihistamine, inhibits histamine release in vivo in the human. Am Rev Respir Dis 1990 0.96
166 Recombinant histamine-releasing factor enhances IgE-dependent IL-4 and IL-13 secretion by human basophils. J Immunol 1997 0.96
167 Anaphylactic relase of a basophil kallikrein-like activity. II. A mediator of immediate hypersensitivity reactions. J Clin Invest 1979 0.96
168 Chlorphenesin: a new inhibitor IgE-mediated histamine release. J Immunol 1969 0.96
169 Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981 0.96
170 Preliminary identification and role of phosphodiesterase isozymes in human basophils. J Immunol 1992 0.95
171 The concept of basophil releasability. J Allergy Clin Immunol 1986 0.95
172 Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 1989 0.95
173 Prolonged maintenance interval in hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981 0.95
174 Release of histamine from human leukocytes stimulated with the tumor-promoting phorbol diesters. I. Characterization of the response. J Immunol 1981 0.95
175 Differences in the volume distributions of human lung mast cell granules and lipid bodies: evidence that the size of these organelles is regulated by distinct mechanisms. J Cell Biol 1985 0.95
176 Failure to obtain histamine release from rat mast cells exposed to human allergic serum and specific antigen or IgE myeloma protein and anti-IgE. J Immunol 1973 0.95
177 Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 1990 0.95
178 Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J Clin Invest 1987 0.95
179 Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J Allergy Clin Immunol 1981 0.95
180 Studies on the allergic and nonallergic nasal inflammation. J Allergy Clin Immunol 1988 0.95
181 Inhibition of T cell-mediated cytotoxicity by anti-inflammatory steroids. J Immunol 1984 0.95
182 Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 1996 0.95
183 Comparison of human lung and intestinal mast cells. J Allergy Clin Immunol 1988 0.94
184 Modulation of histamine release from human basophils in vitro by physiological concentrations of zinc. J Pharmacol Exp Ther 1981 0.94
185 IgE-mediated histamine release from human basophils: differences between antigen E- and anti-IgE-induced secretion. Int Arch Allergy Appl Immunol 1981 0.94
186 The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol 1978 0.94
187 Studies of antigen binding on human basophils. II. Continued expression of antigen-specific IgE during antigen-induced desensitization. J Immunol 1983 0.94
188 Induction of IgE-mediated immediate hypersensitivity to group I rye grass pollen allergen and allergoids in non-allergic man. Immunology 1972 0.94
189 Intestinal mast cell responses in idiopathic inflammatory bowel disease. Histamine release from human intestinal mast cells in response to gut epithelial proteins. Dig Dis Sci 1993 0.94
190 Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000 0.94
191 Dexamethasone does not inhibit the release of mediators from human mast cells residing in airway, intestine, or skin. Am Rev Respir Dis 1989 0.94
192 Functional heterogeneity of human mast cells from different anatomic sites: in vitro responses to morphine sulfate. J Allergy Clin Immunol 1987 0.93
193 Immunoglobulin E-mediated release of a kininogenase from purified human lung mast cells. Am Rev Respir Dis 1985 0.93
194 Differential regulation of human basophil and lung mast cell function by adenosine. J Pharmacol Exp Ther 1991 0.93
195 IL-4 production by human basophils found in the lung following segmental allergen challenge. J Allergy Clin Immunol 2001 0.93
196 Nerve growth factor or IL-3 induces more IL-13 production from basophils of allergic subjects than from basophils of nonallergic subjects. J Allergy Clin Immunol 2001 0.93
197 Allergens of honey bee venom. Arch Biochem Biophys 1976 0.93
198 Defective histamine release in chronic urticaria. J Clin Invest 1976 0.93
199 Qualitative differences between dimeric and trimeric stimulation of human basophils. J Immunol 1983 0.93
200 Local generation of sulfidopeptide leukotrienes upon nasal provocation with cold, dry air. Am Rev Respir Dis 1986 0.92
201 Recombinant human IL-1 alpha and -1 beta potentiate IgE-mediated histamine release from human basophils. J Immunol 1989 0.92
202 Comparative studies of histamine release and potassium efflux from human leukocytes. Proc Soc Exp Biol Med 1966 0.92
203 Isoproterenol-induced inhibition of immunoglobulin E-mediated release of histamine and arachidonic acid metabolites from the human lung mast cell. J Pharmacol Exp Ther 1988 0.92
204 Generation of slow reacting substance by human leukocytes. II. Comparison of stimulation by antigen, anti-IgE, calcium ionophore, and C5-peptide. J Immunol 1980 0.92
205 Characterization of human synovial mast cells. J Rheumatol 1988 0.92
206 The pharmacologic modulation of mediator release from human basophils. J Allergy Clin Immunol 1988 0.92
207 Anaphylaxis after contact with a jellyfish. J Allergy Clin Immunol 1985 0.91
208 An immunoglobulin E-dependent recombinant histamine-releasing factor induces interleukin-4 secretion from human basophils. J Exp Med 1996 0.91
209 Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 1998 0.91
210 IL-3 augments adhesiveness for endothelium and CD11b expression in human basophils but not neutrophils. J Immunol 1990 0.91
211 Immunoglobulin E-mediated degranulation of isolated human lung mast cells. Lab Invest 1985 0.91
212 Antagonism of antigen-induced contraction of guinea pig and human airways. Nature 1977 0.91
213 Measurement of IgG-blocking antibodies: development and application of a radioimmunoassay. J Immunol 1976 0.91
214 IgE-induced changes in human basophil cyclic AMP levels. Int Arch Allergy Appl Immunol 1978 0.91
215 Studies of antigen binding on human basophils. I. Antigen binding and functional consequences. J Immunol 1983 0.91
216 The relationship of in vitro and in vivo allergic histamine release: inhibition in primates by cAMP active agents. Int Arch Allergy Appl Immunol 1972 0.90
217 F-met peptide-induced degranulation of human basophils. Lab Invest 1991 0.90
218 Histamine release due to bivalent penicilloyl haptens: control by the basophil plasma membrane. J Immunol 1978 0.90
219 Immunologic mast cell-mediated responses and histamine release are attenuated by heparin. J Appl Physiol (1985) 1992 0.90
220 The potency and antigen E content of commercially prepared ragweed extracts. J Allergy 1970 0.90
221 Spontaneous histamine release after exposure to hyperosmolar solutions. J Allergy Clin Immunol 1986 0.89
222 Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils. Am J Respir Cell Mol Biol 1994 0.89
223 Possible role of phospholipase A2 in triggering histamine secretion from human basophils in vitro. Clin Immunol Immunopathol 1981 0.89
224 Human mast cells use conservation and condensation mechanisms during recovery from degranulation. In vitro studies with mast cells purified from human lungs. Lab Invest 1986 0.89
225 Histamine release due to bivalent penicilloyl haptens the relation of activation and desensitization of basophils to dynamic aspects of ligand binding to cell surface antibody. J Immunol 1979 0.89
226 Hydrocortisone and human lymphocytes: increases in cyclic adenosine 3':5'-monophosphate and potentiation of adenylate cyclase-activating agents. J Pharmacol Exp Ther 1980 0.88
227 Plasma kallikrein during experimentally induced allergic rhinitis: role in kinin formation and contribution to TAME-esterase activity in nasal secretions. J Immunol 1986 0.88
228 Standardization and efficacy of allergen extracts. N Engl J Med 1976 0.88
229 Degranulation of human basophils: quantitative analysis of histamine release and desensitization, due to a bivalent penicilloyl hapten. J Immunol 1979 0.88
230 Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1991 0.88
231 The pharmacologic modulation of the release of arachidonic acid metabolites from purified human lung mast cells. Am Rev Respir Dis 1985 0.88
232 Inhibition of histamine and prostaglandin D2 release from human lung mast cells by ciclosporin A. Int Arch Allergy Appl Immunol 1989 0.88
233 Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J Immunol 2001 0.88
234 The effects of antihistamines beyond H1 antagonism in allergic inflammation. J Allergy Clin Immunol 1990 0.88
235 Vesicular transport of histamine in stimulated human basophils. Blood 1996 0.88
236 Leukotriene B4 as a mediator of early and late reactions to antigen in humans: the effect of systemic glucocorticoid treatment in vivo. J Allergy Clin Immunol 1989 0.88
237 In vivo and in vitro effects of antihistamines on mast cell mediator release: a potentially important property in the treatment of allergic disease. Ann Allergy 1989 0.87
238 The role of basophils in inflammatory reactions. J Invest Dermatol 1978 0.87
239 The osmolality of nasal secretions increases when inflammatory mediators are released in response to inhalation of cold, dry air. Am Rev Respir Dis 1988 0.87
240 In vivo demonstration of inflammatory mediator release following nasal challenge with antigen. Eur J Respir Dis Suppl 1983 0.87
241 Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol 2001 0.87
242 Diagnostic tests in ragweed-allergic asthma. A comparison of direct skin tests, leukocyte histamine release, and quantitative bronchial challenge. J Allergy Clin Immunol 1974 0.87
243 Selective inhibition of arachidonic acid metabolite release from human lung tissue by antiinflammatory steroids. J Immunol 1986 0.87
244 Capacity of purified antigens and whole pollen extracts to release histamine from leukocytes of hay fever patients. J Allergy Clin Immunol 1973 0.87
245 An evaluation of the role of immunotherapy in asthma. Am Rev Respir Dis 1978 0.87
246 In vitro histamine release from basophils of asthmatic and atopic individuals in D2O. J Immunol 1982 0.87
247 Observations on the pathogenesis of nasal priming. J Allergy Clin Immunol 1989 0.86
248 Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 1994 0.86
249 The effect of indomethacin on immunologic release of histamine and sulfidopeptide leukotrienes from human bronchus and lung parenchyma. Am Rev Respir Dis 1987 0.86
250 Nasal provocation with allergen induces a secondary serum IgE antibody response. J Allergy Clin Immunol 1997 0.86
251 Platelet activation in antigen-induced bronchoconstriction. N Engl J Med 1981 0.86
252 Trials of alum-precipitated pollen extracts in the treatment of hay fever. J Allergy Clin Immunol 1972 0.86
253 The modulation of human basophil histamine release by products of the 5-lipoxygenase pathway. J Immunol 1982 0.86
254 Human mast cells synthesize new granules during recovery from degranulation. In vitro studies with mast cells purified from human lungs. Blood 1988 0.86
255 The role of ragweed pollen in autumnal asthma. J Allergy Clin Immunol 1977 0.86
256 Immunochemical studies of yellowjacket venom proteins. Mol Immunol 1983 0.85
257 Passive sensitization of human basophils: evidence for heterogeneity in the IgE molecule. Int Arch Allergy Appl Immunol 1979 0.85
258 Differences between basophils and mast cells: failure to detect Charcot-Leyden crystal protein (lysophospholipase) and eosinophil granule major basic protein in human mast cells. J Immunol 1986 0.85
259 Comparisons of alum-precipitated and unprecipitated aqueous ragweed pollen extracts in the treatment of hay fever. J Allergy Clin Immunol 1978 0.85
260 A prospective study of the natural history of large local reactions after Hymenoptera stings in children. J Pediatr 1984 0.85
261 Human uterine mast cells. Isolation, purification, characterization, ultrastructure, and pharmacology. J Immunol 1991 0.85
262 IgE-mediated anaphylactic degranulation of isolated human skin mast cells. Blood 1991 0.85
263 Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol 1991 0.85
264 Some invariant properties of IgE-mediated basophil activation and desensitization. J Immunol 1979 0.84
265 Differential regulation of antigen-induced IL-4 and IL-13 generation from T lymphocytes by IFN-alpha. J Allergy Clin Immunol 1999 0.84
266 Suppression of late-phase skin reactions by immunotherapy with ragweed extract. J Allergy Clin Immunol 1985 0.84
267 Protection against anaphylaxis in hymenoptera-sensitive patients by passive immunization. Monogr Allergy 1977 0.84
268 Activation of basophils. Fed Proc 1986 0.84
269 Eosinophils chemotactic factor (ECF). IV. Inhibitory activity in human peripheral leukocytes. Int Arch Allergy Appl Immunol 1978 0.84
270 Cyclic nucleotides in immune responses and allergy. Adv Cyclic Nucleotide Res 1980 0.84
271 Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. J Allergy Clin Immunol 1989 0.84
272 Generation of leukotriene B4 by human lung fragments and purified human lung mast cells. Am Rev Respir Dis 1988 0.84
273 Sequential analysis of the allergic response: cyclic AMP, calcium and histamine. Int Arch Allergy Appl Immunol 1975 0.84
274 Lipoxygenase products of arachidonic acid: role in modulation of IgE-induced histamine release. Adv Prostaglandin Thromboxane Leukot Res 1982 0.84
275 Activation of Hageman factor by proteases released during antigen challenge of human lung. Trans Assoc Am Physicians 1981 0.84
276 A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980 0.84
277 Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981 0.84
278 Morphologic mast cell cycles. Cell Immunol 1987 0.84
279 Anaphylactic release of a prekallikrein activator from human lung in vitro. J Clin Invest 1983 0.84
280 Reversed in vitro anaphylaxis induced by anti-IgG: specificity of the reaction and comparison with antigen-induced histamine release. J Immunol 1972 0.84
281 Is desensitization' for ragweed hay fever immunologically specific? Int Arch Allergy Appl Immunol 1972 0.84
282 Anaphylaxis and stinging insect hypersensitivity. JAMA 1987 0.83
283 Prostaglandin D2 and histamine during the immediate and the late-phase components of allergic cutaneous responses. J Allergy Clin Immunol 1988 0.83
284 Allergy to insect sting. III. Allergenic cross-reactivity among the vespid venoms. J Allergy Clin Immunol 1976 0.83
285 Separation of major prostaglandins, leukotrienes, and monoHETEs by high performance liquid chromatography. J Immunol Methods 1983 0.83
286 Clinical and immunologic observations in patients who stop venom immunotherapy. J Allergy Clin Immunol 1986 0.83
287 Eosinophil chemotactic factor (ECF). III. Generation in human peripheral leukocytes. Int Arch Allergy Appl Immunol 1978 0.83
288 GM-CSF regulates human eosinophil responses to F-Met peptide and platelet activating factor. J Immunol 1993 0.83
289 A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980 0.83
290 Appearance of granulocyte-macrophage colony-stimulating factor activity at allergen-challenged cutaneous late-phase reaction sites. J Immunol 1993 0.83
291 Studies on ragweed pollen allergens. V. Ann Allergy 1967 0.83
292 Inflammatory mediators and mechanisms of release from purified human basophils and mast cells. J Allergy Clin Immunol 1984 0.83
293 Production of granulocyte/macrophage colony-stimulating factor in human airways during allergen-induced late-phase reactions in atopic subjects. Lymphokine Cytokine Res 1992 0.83
294 Inflammatory mediators in nasal secretions during induced rhinitis. Clin Allergy 1986 0.83
295 Maintenance immunotherapy in ragweed hay fever. Booster injections at six week intervals. J Allergy 1971 0.83
296 Differential release of mediators from human basophils: differences in arachidonic acid metabolism following activation by unrelated stimuli. J Leukoc Biol 1989 0.82
297 Demonstration of inhibition of mediator release from human mast cells by azatadine base. In vivo and in vitro evaluation. JAMA 1986 0.82
298 Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation. J Allergy Clin Immunol 1998 0.82
299 Abnormalities of basophil "releasability" in atopic and asthmatic individuals. J Allergy Clin Immunol 1986 0.82
300 Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 1992 0.82
301 Cells and secretagogues involved in the human late-phase response. Int Arch Allergy Appl Immunol 1989 0.82
302 Preparation and immunochemical properties of methoxypolyethylene glycol-coupled and N-carboxymethylated derivatives of ragweed pollen allergen, antigen E. Arch Biochem Biophys 1977 0.82
303 Basic characteristics of human lung mast cell desensitization. J Immunol 1987 0.82
304 The role of the basophil in allergic inflammation. Allergy 1995 0.82
305 Studies on the relationships between sensitivity to cold, dry air, hyperosmolal solutions, and histamine in the adult nose. Am Rev Respir Dis 1990 0.82
306 Human allergic reactions. Am J Med 1969 0.82
307 Modulation of the release of histamine and arachidonic acid metabolites from human basophils and mast cells by auranofin. Agents Actions 1986 0.82
308 Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Pharmacol Exp Ther 1997 0.82
309 Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin Exp Allergy 1998 0.82
310 Differential regulation of human, antigen-specific Th1 and Th2 responses by the B-7 homologues, CD80 and CD86. Am J Respir Cell Mol Biol 1997 0.82
311 A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982 0.82
312 In vitro assay of allergenic properties of ragweed pollen antigens. J Allergy 1966 0.82
313 Preferential recruitment of activated, memory T lymphocytes into skin chamber fluids during human cutaneous late-phase allergic reactions. J Allergy Clin Immunol 1995 0.82
314 Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol 1998 0.82
315 Allergy to insect stings. IV. Diagnosis by radioallergosorbent test (R.A.S.T.). J Immunol 1978 0.82
316 Mediator release from human basophils and mast cells from lung and intestinal mucosa. Int Arch Allergy Appl Immunol 1985 0.82
317 Serum IgE level drives basophil and mast cell IgE receptor display. Int Arch Allergy Immunol 1997 0.81
318 An ultrastructural analysis of tumor-promoting phorbol diester-induced degranulation of human basophils. Am J Pathol 1992 0.81
319 Purified human basophils and mast cells: current concepts of mediator release. Eur J Respir Dis Suppl 1983 0.81
320 Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones. Biochem Pharmacol 1997 0.81
321 The role of complement in human immediate hypersensitivity: evidence against involvement of the alternate pathway of complement activation. J Immunol 1973 0.81
322 Evaluation of the quantity and affinity of human IgG "blocking" antibodies. J Immunol 1979 0.81
323 Diabetes insipidus with hypersensitivity to pitressin. An immunological study. Johns Hopkins Med J 1972 0.81
324 Purification of immunoglobulin E (IgE) antibodies from sera with high IgE titers. J Immunol Methods 1995 0.81
325 The heterogeneity of human IgE exemplified by the passive transfer of D2O sensitivity. Clin Exp Allergy 1991 0.81
326 Histamine-releasing factors and heterogeneity of IgE. Springer Semin Immunopathol 1990 0.81
327 Basophil mediators and their release, with emphasis on BK-A. J Invest Dermatol 1980 0.81
328 Intranasal beclomethasone inhibits antigen-induced nasal hyperresponsiveness to histamine. J Allergy Clin Immunol 1992 0.81
329 Failure of the putative IgE pentapeptide to compete with IgE for receptors on basophils and masts cells. Int Arch Allergy Appl Immunol 1977 0.81
330 Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol 1982 0.81
331 Release of histamine from human leukocytes stimulated with the tumor-promoting phorbol diesters. II. Interaction with other stimuli. J Immunol 1982 0.81
332 Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 1989 0.81
333 The action of strontium on basophil leukocytes and its use to probe the relationship between immunologic stimulus and secretory response. J Immunol 1979 0.81
334 Antigen-provoked increase in histamine reactivity. Observations on mechanisms. Am Rev Respir Dis 1991 0.81
335 Arachidonic acid metabolites during nasal challenge. Arch Otolaryngol Head Neck Surg 1987 0.81
336 IgE-mediated basophil phenomena: quantitation, control, inflammatory interactions. Immunol Rev 1978 0.80
337 In vivo model for the evaluation of topical antiallergic medications. Arch Otolaryngol 1984 0.80
338 Histamine release from human leukocytes: relationships between cyclic nucleotide, calcium, and antigen concentrations. J Immunol 1975 0.80
339 IgE mediated histamine release: in vitro separation into two phases. Int Arch Allergy Appl Immunol 1971 0.80
340 An inhibitor of lipoxygenase inhibits histamine release from human basophils. Clin Immunol Immunopathol 1980 0.80
341 Effects of loratadine and terfenadine on the induced nasal allergic reaction. Arch Otolaryngol Head Neck Surg 1996 0.80
342 Kinetic analysis of histamine release due to covalently linked IgE dimers. Mol Immunol 1982 0.80
343 A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997 0.80
344 The allergens responsible for house dust allergy. J Allergy Clin Immunol 1972 0.80
345 The mechanism of mediator release from human basophils induced by platelet-activating factor. J Immunol 1990 0.80
346 Control mechanisms of histamine release from human basophils in vitro: the role of phospholipase A2 and of lipoxygenase metabolites. Int Arch Allergy Appl Immunol 1981 0.80
347 Physiologic responses and histamine release after nasal antigen challenge. Effect of atropine. Am J Respir Crit Care Med 1994 0.80
348 Histamine distribution in human basophil secretory granules undergoing FMLP-stimulated secretion and recovery. Blood 1995 0.80
349 Mechanisms of contraction induced by partially purified slow reacting substance from human polymorphonuclear leukocytes and leukotriene D in guinea pig ileal smooth muscle. J Immunol 1981 0.80
350 Protein allergens of white-faced hornet, yellow hornet, and yellow jacket venoms. Biochemistry 1978 0.80
351 Clinical and immunologic effects of component peptides in Allervax Cat. Int Arch Allergy Immunol 1997 0.80
352 Adenosine-adenosine deaminase modulation of histamine release from human basophils in vitro. Ric Clin Lab 1980 0.80
353 Cyclic AMP agonist inhibition increases at low levels of histamine release from human basophils. J Pharmacol Exp Ther 1981 0.79
354 Regulation of IgE-dependent IL-4 generation by human basophils treated with glucocorticoids. J Immunol 1997 0.79
355 Recombinant stem cell factor-induced mast cell activation and smooth muscle contraction in human bronchi. Am J Respir Cell Mol Biol 1994 0.79
356 Activated human basophils contain histamine in cytoplasmic vesicles. Int Arch Allergy Immunol 1994 0.79
357 Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils. J Immunol 1992 0.79
358 An epidemiologic study of insect allergy in children. I. Characteristics of the disease. J Pediatr 1982 0.79
359 Prospective observations on stopping prolonged venom immunotherapy. J Allergy Clin Immunol 1989 0.79
360 Heterogeneity of human mast cells and basophils. Effects of a putative 5-lipoxygenase inhibitor. Biochem Pharmacol 1989 0.79
361 Assessment of prolonged venom immunotherapy in children. J Allergy Clin Immunol 1987 0.79
362 Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells. Am J Respir Cell Mol Biol 1995 0.79
363 Mediator release after allergic and physical nasal challenges. Int Arch Allergy Appl Immunol 1985 0.79
364 Theophylline reduces histamine release during pollen-induced rhinitis. J Allergy Clin Immunol 1986 0.79
365 The pathophysiology of human mast cells. In vitro and in vivo function. Am Rev Respir Dis 1987 0.79
366 Effect of theophylline and terbutaline on immediate skin tests. J Allergy Clin Immunol 1980 0.79
367 Effect of prostaglandin D2 in modulating histamine release from human basophils. J Pharmacol Exp Ther 1984 0.79
368 Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J Allergy Clin Immunol 1997 0.79
369 Is histamine responsible for the symptoms of rhinovirus colds? A look at the inflammatory mediators following infection. Pediatr Infect Dis J 1988 0.79
370 The role of inhalation challenge. Int Arch Allergy Appl Immunol 1975 0.78
371 Mechanisms and pharmacologic control of basophil-derived IL-4 and IL-13. Int Arch Allergy Immunol 1999 0.78
372 Beta-adrenergic blockers, immunotherapy, and skin testing. American Academy of Allergy and Immunology. J Allergy Clin Immunol 1989 0.78
373 Comparison between skin-sensitizing antibody titers and leukocyte sensitivity measurements as an index of the severity of ragweed hay fever. J Allergy 1967 0.78
374 IgE-dependent histamine-releasing factors. A brief review. Int Arch Allergy Appl Immunol 1991 0.78
375 Activation of human Hageman factor by a leukocytic protease. Adv Exp Med Biol 1979 0.78
376 Profile of prostanoid release following antigen challenge in vivo in the skin of man. Br J Dermatol 1991 0.78
377 Origin of PGF2 alpha production following anaphylactic challenge of human lung. Monogr Allergy 1979 0.78
378 Rapidly released allergens from short ragweed pollen. I. Kinetics of release of known allergens in relation to biologic activity. J Allergy Clin Immunol 1981 0.78
379 Inhibition by adenosine of histamine and leukotriene release from human basophils. Biochem Pharmacol 1989 0.78
380 Effects of a specific inhibitor of the 5-lipoxygenase pathway on mediator release from human basophils and mast cells. J Pharmacol Exp Ther 1988 0.78
381 Experimentally induced nasal allergic responses. J Allergy Clin Immunol 1988 0.78
382 The pharmacologic control of mediator release from human basophils and mast cells. Respiration 1986 0.78
383 Histamine release in acute anaphylactic enteropathy of the rat. J Immunol 1984 0.78
384 The effect of terfenadine on unilateral nasal challenge with allergen. J Allergy Clin Immunol 1994 0.78
385 Substance P activates the release of histamine from human skin mast cells through a pertussis toxin-sensitive and protein kinase C-dependent mechanism. Clin Immunol Immunopathol 1996 0.78
386 Generation and release of eosinophil chemotactic factor from human polymorphonuclear leukocytes. Monogr Allergy 1977 0.78
387 Spontaneous histamine secretion from leukocytes in the presence of strontium. J Pharmacol Exp Ther 1979 0.78
388 Sensitization following Hymenoptera whole body extract therapy. J Allergy Clin Immunol 1978 0.78
389 IgA, IgG and IgM quantification in bronchoalveolar lavage fluids from allergic rhinitics, allergic asthmatics, and normal subjects by monoclonal antibody-based immunoenzymetric assays. J Immunol Methods 1995 0.78
390 Cytokine generation by human basophils. J Allergy Clin Immunol 1994 0.78
391 Inhibitability and enhanceability of basophil histamine release in asthmatic and normal subjects. Int Arch Allergy Appl Immunol 1985 0.78
392 The effect of cetirizine on early allergic response. Laryngoscope 1989 0.78
393 Mechanisms of mediator release from human skin mast cells upon stimulation by the bradykinin analog, [DArg0-Hyp3-DPhe7]bradykinin. Biochem Pharmacol 1991 0.78
394 Theophylline reduces the response to nasal challenge with antigen. Am J Med 1985 0.78
395 Lipid mediators of the allergic reaction. Chem Immunol 1990 0.78
396 Comparative ultrastructural morphology of human basophils stimulated to release histamine by anti-IgE, recombinant IgE-dependent histamine-releasing factor, or monocyte chemotactic protein-1. J Allergy Clin Immunol 1996 0.77
397 Augmentation of antigen-stimulated histamine release from human basophils by serum-treated zymosan particles. I. Characteristics of enhancement. J Immunol 1979 0.77
398 Protein kinase C modulates immunoglobulin E-mediated activation of human mast cells from lung and skin. I. Pharmacologic inhibition. J Pharmacol Exp Ther 1991 0.77
399 Ultrastructural autoradiographic analysis of RNA in isolated human lung mast cells during secretion and recovery from secretion. Int Arch Allergy Immunol 2000 0.77
400 Dexamethasone inhibits the antigen-induced contractile activity and release of inflammatory mediators in isolated guinea pig lung tissue. Am Rev Respir Dis 1987 0.77
401 RNA is closely associated with human mast cell secretory granules, suggesting a role(s) for granules in synthetic processes. J Histochem Cytochem 2000 0.77
402 A reevaluation of immunotherapy for asthma. Am Rev Respir Dis 1984 0.77
403 The effect of azelastine on the early allergic response. Clin Exp Allergy 1992 0.77
404 Nasal secretory antibody to inhalant allergens in allergic and non-allergic patients. Immunology 1970 0.77
405 Augmentation of antigen-stimulated histamine release from human basophils by serum-treated zymosan particles. II. Dependence on IgE-mediated release. J Immunol 1979 0.77
406 Mast cells and mast cell mediators in models of airway disease. Prog Clin Biol Res 1985 0.77
407 Vesicular transport of Charcot-Leyden crystal protein in tumor-promoting phorbol diester-stimulated human basophils. Lab Invest 1996 0.77
408 Induction of histamine release from human skin mast cells by bradykinin analogs. Biochem Pharmacol 1989 0.77
409 Pharmacologic control of histamine release from human basophils induced by platelet-activating factor. Int Arch Allergy Immunol 1993 0.77
410 Human experimentation by industry: the case of "enzyme" detergents. Ann Intern Med 1971 0.77
411 Relationship between the early, late, and rechallenge reaction to nasal challenge with antigen: observations on the role of inflammatory mediators and cells. J Allergy Clin Immunol 1990 0.77
412 Modulation of mediator release from human basophils and pulmonary mast cells and macrophages by auranofin. Biochem Pharmacol 1990 0.77
413 Adenosine receptors on human basophils and lung mast cells. Adv Exp Med Biol 1986 0.77
414 Histamine-containing cells in human peritoneal fluid. J Immunol 1984 0.77
415 Immunochemical studies of dextran coupled ragweed pollen allergen, antigen E. Arch Biochem Biophys 1975 0.77
416 Allergic responses to airborne allergens and insect venoms. Fed Proc 1977 0.77
417 The role of kinins in human allergic disease. N Engl Reg Allergy Proc 1987 0.77
418 Co-regulation of antigen-specific T lymphocyte responses by type I and type II cyclic AMP-dependent protein kinases (cAK). Biochem Pharmacol 1998 0.77
419 Treatment of ragweed hay fever with urea-denatured antigen E. J Allergy Clin Immunol 1980 0.77
420 Local application of atropine attenuates the upper airway reaction to cold, dry air. Am Rev Respir Dis 1992 0.77
421 The role of prostaglandin D2 in IgE-mediated reactions in man. Trans Assoc Am Physicians 1982 0.77
422 Inhibition of human basophil leukotriene release by antiinflammatory steroids. Int Arch Allergy Appl Immunol 1985 0.77
423 The interaction of cytokines with human basophils and mast cells. Int Arch Allergy Immunol 1995 0.77
424 Cold dry air-induced rhinitis: effect of inhalation and exhalation through the nose. J Appl Physiol (1985) 1995 0.77
425 Unilateral nasal allergen challenge leads to bilateral release of prostaglandin D2. Clin Exp Allergy 1996 0.76
426 IgE and IgG antibody response to purified bee-venom antigens and peptides in four patients who had adverse reactions to immunotherapy. Clin Allergy 1988 0.76
427 Lectins do not distinguish between heterogenous IgE molecules as defined by differential activity of an IgE-dependent histamine releasing factor. J Allergy Clin Immunol 1996 0.76
428 The development of negative skin tests in children treated with venom immunotherapy. J Allergy Clin Immunol 1984 0.76
429 Is leukotriene B4 an important mediator in human IgE-mediated allergic reactions? Am Rev Respir Dis 1987 0.76
430 Inhibition of human polymorphonuclear leukocyte-derived histaminase activity by H-2 antagonists. Biochem Pharmacol 1978 0.76
431 Treatment failures with whole-body extract therapy of insect sting allergy. JAMA 1981 0.76
432 Bradykinin analog induce histamine release from human skin mast cells. Adv Exp Med Biol 1989 0.76
433 H2 antihistamines augment antigen-induced histamine release from human basophils in vitro. J Immunol 1982 0.76
434 Platelet augmentation of IgE-dependent histamine release from human basophils and mast cells. Int Arch Allergy Appl Immunol 1984 0.76
435 Studies of the intracellular Ca2+ levels in human adult skin mast cells activated by the ligand for the human c-kit receptor and anti-IgE. Biochem Pharmacol 1994 0.76
436 Interferon-beta induces selective enhancement of antigen-specific T cell responses. J Interferon Cytokine Res 2000 0.76
437 Deuterium-oxide-induced histamine release from basophils of allergic subjects. I. Responsiveness to deuterium oxide requires an activation step. Am Rev Respir Dis 1984 0.76
438 Function and expression of adhesion molecules on human basophils. J Allergy Clin Immunol 1994 0.76
439 Immunotherapy in bee-sting anaphylaxis. Use of honeybee venom. JAMA 1975 0.75
440 Anaphylaxis during autologous peripheral blood progenitor cell infusion. Bone Marrow Transplant 1997 0.75
441 Basophils and eosinophils in allergic rhinitis. J Allergy Clin Immunol 1994 0.75
442 Paclitaxel hypersensitivity revisited. J Clin Oncol 1996 0.75
443 Disassociation of the release of histamine and arachidonic acid metabolites from osmotically activated basophils and human lung mast cells. Am Rev Respir Dis 1990 0.75
444 Diagnosis and treatment of anaphylactic reactions to Hymenoptera stings in children. J Pediatr 1980 0.75
445 Human anaphylaxis. West J Med 1986 0.75
446 Immunologic responses to conjugates of antigen E in patients with ragweed hay fever. J Allergy Clin Immunol 1984 0.75
447 The effect of a leukotriene antagonist on the early response to antigen. Otolaryngol Head Neck Surg 1990 0.75
448 Alkaline earth ions and the secretion of enzymes from human neutrophil leucocytes [proceedings]. Br J Pharmacol 1979 0.75
449 Case report of venom immunotherapy for a patient with large local reactions. Ann Allergy Asthma Immunol 2001 0.75
450 Prevention of canine anaphylaxis with isoproterenol. Am Rev Respir Dis 1986 0.75
451 Kininogens in nasal secretions after allergen challenge. Adv Exp Med Biol 1986 0.75
452 Antibody response following immunotherapy in ragweed hay fever: Allpyral vs. whole ragweed extract. J Allergy 1968 0.75
453 Limited proteolysis of antigens E and K from ragweed pollen. Arch Biochem Biophys 1981 0.75
454 Purified human basophils do not generate LTB4. Biochem Pharmacol 1987 0.75
455 Diamine oxidase-gold ultrastructural localization of histamine in isolated human lung mast cells stimulated to undergo anaphylactic degranulation and recovery in vitro. J Leukoc Biol 1996 0.75
456 The effects of H1 antihistamines on the early allergic response. Ann Allergy 1989 0.75
457 In vitro resistance to dexamethasone of basophils from patients receiving long-term steroid therapy. Am Rev Respir Dis 1985 0.75
458 Nasal challenge with cold, dry air induces a late-phase reaction. Am Rev Respir Dis 1988 0.75
459 Mechanisms of basophil recruitment in allergic diseases. Clin Exp Allergy 1992 0.75
460 Effects of a single-dose pretreatment with captopril on the immediate response to nasal challenge with allergen. Int Arch Allergy Appl Immunol 1990 0.75
461 Bilateral increases in histamine after unilateral nasal allergen challenge. Am J Respir Crit Care Med 1997 0.75
462 The allergic state and the state of allergy. Med Times 1970 0.75
463 Recovery of human basophils after FMLP-stimulated secretion. Clin Exp Allergy 1996 0.75
464 Modulation of the rate of histamine release from basophils by cyclic AMP. Eur J Pharmacol 1980 0.75
465 Diamine oxidase-gold labels histamine in human mast-cell granules: a new enzyme-affinity ultrastructural method. J Histochem Cytochem 1993 0.75
466 Detection of allergen- and mitogen-induced human cytokine transcripts using a competitive polymerase chain reaction. J Immunol Methods 1994 0.75
467 Mediator release from human lung under conditions of reduced oxygen tension. J Pharmacol Exp Ther 1986 0.75
468 Human mast cells and basophils--structure, function, pharmacology, and biochemistry. Clin Rev Allergy 1983 0.75
469 Justifying a mechanism-based specialty. J Allergy Clin Immunol 1996 0.75
470 Kinins as mediators of human allergic reactions. Adv Exp Med Biol 1986 0.75
471 Diagnosis of Hymenoptera hypersensitivity by skin testing with Hymenoptera venoms. J Allergy Clin Immunol 1977 0.75
472 Indomethacin, arachidonic acid metabolism and basophil histamine release. Monogr Allergy 1979 0.75
473 Studies with purified human basophils and mast cells. Monogr Allergy 1983 0.75
474 Antigen- and histamine H1 receptor-mediated relaxation of guinea pig isolated trachea. Eur J Pharmacol 1987 0.75
475 Cutaneous IgE-mediated inflammatory lesion size is inhibited by an H1 antagonist (terfenadine) while mediator release is unaffected in vivo and in vitro. Clin Exp Allergy 1993 0.75
476 Pharmacology of upper airways challenge. Int Arch Allergy Appl Immunol 1987 0.75
477 Effects of antihistamines on the cardiopulmonary changes due to canine anaphylaxis. J Appl Physiol (1985) 1988 0.75
478 Once stung, twice shy. When should insect sting allergy be treated? JAMA 1980 0.75
479 Hymenoptera sensitivity. Diagnostic and therapeutic studies. Int Arch Allergy Appl Immunol 1975 0.75
480 In vitro approach to problems in clinical allergy. N Y State J Med 1968 0.75
481 Histamine release from human basophils is induced by IgE-dependent factor(s) derived from human lung macrophages and an Fc epsilon receptor-positive human B cell line. Trans Assoc Am Physicians 1985 0.75
482 Penicillin hypersensitivity in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1975 0.75
483 Effect of solvent on the histamine-releasing, enzyme-releasing, and mitogenic properties of the calcium ionophore A23187. Immunopharmacology 1979 0.75
484 Pharmacologic control of IgE-mediated histamine release from human leukocytes. Int Arch Allergy Appl Immunol 1973 0.75
485 The role of leukotrienes in human pathophysiology. Ann N Y Acad Sci 1988 0.75
486 IL-4 secretion and histamine release by human basophils are differentially regulated by protein kinase C activation. J Leukoc Biol 1998 0.75
487 Localized antigen challenge of the nasal mucosa. Arch Otolaryngol Head Neck Surg 1990 0.75
488 Chlorphenesin: a new inhibitor of IgE-mediated histamine release. J Immunol 1969 0.75
489 Basophil kallikrein of anaphylaxis (BK-A)--purification and characterization. Adv Exp Med Biol 1979 0.75
490 [The role of primary chemical mediators in anaphylactic and inflammatory reactions]. Minerva Med 1982 0.75
491 Origin of late phase histamine release. J Allergy Clin Immunol 1996 0.75
492 Treatment with hot, humid air reduces the nasal response to allergen challenge. J Allergy Clin Immunol 1997 0.75
493 IgE-mediated leukotriene release in vitro and in vivo. Trans Assoc Am Physicians 1984 0.75
494 An antigen-activated DFP-inhibitable enzyme controls basophil desensitization. J Immunol 1984 0.75
495 Analysis of mast cell activation using diamine oxidase-gold enzyme-affinity ultrastructural cytochemistry. Int Arch Allergy Immunol 1995 0.75
496 The role of cyclic AMP in inhibiting the IgE-mediated release of histamine. Ann N Y Acad Sci 1971 0.75
497 Localization of Charcot-Leyden crystal protein in individual morphological phenotypes of human basophils stimulated by f-Met peptide. Clin Exp Allergy 1997 0.75
498 The role of adenosine in the control of immune function. Ric Clin Lab 1981 0.75
499 Antigen-induced eosinophil chemotactic factor (ECF) release by human leukocytes. Inflammation 1976 0.75
500 Measurement of circulating IgG and IgE food-immune complexes. J Allergy Clin Immunol 1988 0.75
501 Defective release of eosinophil chemotactic factor from peripheral leukocytes in patients with chronic urticaria. J Invest Dermatol 1976 0.75
502 Quantitative inhalation bronchial challenge in ragweed hay fevery patients: a comparison with ragweed-allergic asthmatics. J Allergy Clin Immunol 1975 0.75
503 The effect of a histamine synthesis inhibitor on the immediate nasal allergic reaction. Allergy 1987 0.75
504 Evaluation of a bedtime dose of a combination antihistamine/analgesic/decongestant product on antigen challenge the next morning. Laryngoscope 1992 0.75
505 Postscript to bee stings: delayed 'serum sickness'. Hosp Pract (Off Ed) 1983 0.75
506 Treatment of immediate hypersensitivity reactions to drugs. Ration Drug Ther 1974 0.75
507 In vitro studies of rye grass pollen antigens. J Allergy 1969 0.75
508 [Treatment of immediate drug hypersensitivity]. Internist (Berl) 1975 0.75
509 The pattern and kinetics in human skin of erythema and mediators during the acute and late-phase response (LPR). J Allergy Clin Immunol 1989 0.75
510 Nearly fatal anaphylaxis following an insect sting. Ann Allergy 1994 0.75
511 Mediators and the mechanism of their release. Chest 1978 0.75
512 Histamine release from human basophils induced by platelet activating factor: the role of extracellular calcium, interleukin-3, and granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol 1995 0.75
513 Vesicular transport of Charcot-Leyden crystal protein in f-Met peptide-stimulated human basophils. Int Arch Allergy Immunol 1997 0.75
514 Heterogeneity of human Fc epsilon RI-bearing cells. Ciba Found Symp 1989 0.75
515 A comparative study of the effects of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine and platelet activating factor on histamine and leukotriene C4 release from human leukocytes. J Allergy Clin Immunol 1993 0.75
516 Observations on nasal late phase reactions. Immunol Invest 1988 0.75
517 Clinical pharmacology of acute allergic disorders. Annu Rev Med 1980 0.75
518 Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1986 0.75
519 Histamine acting on a histamine type 1 (H1) receptor increases beta-glucuronidase release from human lung macrophages. Am J Respir Cell Mol Biol 1990 0.75
520 Effect of oxymetazoline on the early response to nasal challenge with antigen. J Allergy Clin Immunol 1993 0.75
521 Steroid-induced reduction of histamine release does not alter the clinical nasal response to cold, dry air. Am Rev Respir Dis 1991 0.75
522 Immunosuppression in vivo by cholera enterotoxin of the immune response to transplantation antigens. Surg Forum 1973 0.75
523 Sensitization to the enzymes in detergents. J Allergy 1971 0.75
524 Ketotifen reduces sneezing but not histamine release following nasal challenge with antigen. Clin Exp Allergy 1990 0.75
525 In vitro basophil histamine release induced by mannitol in a patient with a mannitol-induced anaphylactoid reaction. J Allergy Clin Immunol 1984 0.75